BR112013003471A2 - solução de testosterona, e, método para tratar deficiência de testosterona - Google Patents

solução de testosterona, e, método para tratar deficiência de testosterona

Info

Publication number
BR112013003471A2
BR112013003471A2 BR112013003471A BR112013003471A BR112013003471A2 BR 112013003471 A2 BR112013003471 A2 BR 112013003471A2 BR 112013003471 A BR112013003471 A BR 112013003471A BR 112013003471 A BR112013003471 A BR 112013003471A BR 112013003471 A2 BR112013003471 A2 BR 112013003471A2
Authority
BR
Brazil
Prior art keywords
testosterone
treating
solution
deficiency
levels
Prior art date
Application number
BR112013003471A
Other languages
English (en)
Inventor
Wilhelmus Henricus Maria Merkus Franciscus
Original Assignee
Innotesto Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innotesto Bvba filed Critical Innotesto Bvba
Publication of BR112013003471A2 publication Critical patent/BR112013003471A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

solução de testosterona, e, método para tratar deficiência de testosterona. soluções de testosterona para a admistração orumucósica que fornece um aumento nos níveis de testosterona sérica em indivíduos deficientes nos níveis de testosterona endógena, e métodos farmacêuticos para fornecer um aumento nos níveis de testosterona sérica e métodos para tratar uma doença ou um sintoma associados com níveis endógenos deficientes de testosterona.
BR112013003471A 2010-08-16 2011-08-09 solução de testosterona, e, método para tratar deficiência de testosterona BR112013003471A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1013701.6A GB2482868A (en) 2010-08-16 2010-08-16 A testosterone liquid spray formulation for oromucosal administration
PCT/EP2011/004031 WO2012022446A1 (en) 2010-08-16 2011-08-09 Testosterone solutions for the treatment of testosterone deficiency

Publications (1)

Publication Number Publication Date
BR112013003471A2 true BR112013003471A2 (pt) 2019-09-24

Family

ID=42938015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003471A BR112013003471A2 (pt) 2010-08-16 2011-08-09 solução de testosterona, e, método para tratar deficiência de testosterona

Country Status (12)

Country Link
US (1) US9498436B2 (pt)
EP (1) EP2605778B1 (pt)
JP (1) JP5816690B2 (pt)
CN (1) CN103118684A (pt)
AU (1) AU2011291075B2 (pt)
BR (1) BR112013003471A2 (pt)
CA (1) CA2807405A1 (pt)
DK (1) DK2605778T3 (pt)
ES (1) ES2539582T3 (pt)
GB (1) GB2482868A (pt)
WO (1) WO2012022446A1 (pt)
ZA (1) ZA201300858B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010038259B4 (de) 2010-10-19 2013-02-07 4Jet Sales + Service Gmbh Verfahren und Vorrichtung zum Gravieren eines flexiblen Bands
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
WO2014083432A2 (en) * 2012-11-14 2014-06-05 Trimel Biopharma Srl Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
ITUB20161027A1 (it) 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
CN112020361A (zh) * 2018-02-02 2020-12-01 阿克罗斯生物制药公司 睾酮治疗方法
CN108524485A (zh) * 2018-02-24 2018-09-14 中山大学 一种猴睾酮缺乏模型的建立方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
WO1990001320A1 (en) * 1988-08-15 1990-02-22 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
EP0910339B1 (en) 1996-04-12 2005-02-02 Novadel Pharma Inc. Buccal polar spray
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
JP4740589B2 (ja) * 2002-04-29 2011-08-03 グラクソ グループ リミテッド 警告システム
AU2004283431B2 (en) 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
EP1872774A1 (en) * 2006-06-07 2008-01-02 Familplan Consulting Ltd Oy A pharmaceutical composition adapted for oral transmucosal administration comprising sex hormone and its use

Also Published As

Publication number Publication date
JP5816690B2 (ja) 2015-11-18
ES2539582T3 (es) 2015-07-02
US20130143851A1 (en) 2013-06-06
GB2482868A (en) 2012-02-22
US9498436B2 (en) 2016-11-22
JP2013534228A (ja) 2013-09-02
CA2807405A1 (en) 2012-02-23
CN103118684A (zh) 2013-05-22
GB201013701D0 (en) 2010-09-29
DK2605778T3 (en) 2015-06-15
AU2011291075B2 (en) 2015-02-05
WO2012022446A1 (en) 2012-02-23
AU2011291075A1 (en) 2013-03-28
EP2605778A1 (en) 2013-06-26
EP2605778B1 (en) 2015-03-25
ZA201300858B (en) 2015-09-30

Similar Documents

Publication Publication Date Title
BR112013003471A2 (pt) solução de testosterona, e, método para tratar deficiência de testosterona
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112017008284A8 (pt) Bifidobactérias ativadas e métodos para uso das mesmas
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
BR112012030592A2 (pt) uso de composição nutricional enteral líquida, composição nutricional enteral líquida, método de prevenção ou tratamento de má nutrição ou baixa nutrição ou de reduzir o risco de ocorrência de má nutrição ou baixa nutrição em pacientes que sofrem de disfagia e método de prevenção ou tratamento de disfagia em mamíferos em risco de disfagia
CR20110198A (es) Fijación de modo en el dominio de fourier
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112014002618A2 (pt) anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmaceutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de cãncer
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112014002614A2 (pt) anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmacêutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de câncer
BR112014030282A2 (pt) métodos de tratamento de excesso de peso e obesidade
BR112015015870A2 (pt) composição farmacêutica
BR112012021081A2 (pt) método e composições para tratar condições hemorrágicas do cérebro
BR112014003123A2 (pt) método implementado em computador e meios de armazenamento legíveis por computador
BR112014015386A2 (pt) método automatizado e dispositivo para limpeza de máquina de gelo combinada
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112015002295A2 (pt) métodos e composições para indução in vivo de formação de célula beta pancreática
PH12016501051A1 (en) Methods of treasting and preventing alloantibody driven chronic graft versus host disease

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.